Upcoming Events
Log In
Pricing
Free Trial

Wk 5, Case 5 - Practice

HIDE

Male with history of metastatic hormone sensitive prostate cancer, status post radical prostatectomy, presenting for evaluation for treatment planning.

PSA levels:

  • 40.6 ng/mL on 2/2/2022
  • 28 ng/mL on 4/6/2022
  • 25.1 ng/mL on 5/18/2020

A PET CT was ordered using the PSMA tracer.

What is likely the cause of the rising PSA level in this patient status post radical prostatectomy?

PrevNext

Report

Faculty

Riham El Khouli, MD

Associate Professor of Radiology, Chief, Division of Nuclear Medicine/Molecular Imaging & Radiotheranostics

University of Kentucky

Michael F. Shriver, MD

Director of Nuclear Medicine

Proscan-NCH Imaging

Tags

PET

Nuclear Medicine

CT

© 2025 Medality. All Rights Reserved.

Contact UsTerms of UsePrivacy Policy